Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 7, 1999, Pages 409-416

  De Mitrio, V ^a,c   Marino, R ^a   Scaraggi, F A ^a   Di Bari, L ^a   Giannoccaro, F ^a   Petronelli, M ^a   Ranieri, P ^b   Tannoia, N ^b   Schiraldi, O ^a  

^a Centro Emostasi e Trombosi   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c NONE   (Italy)

Author keywords

Activated protein C resistance; Factor V Leiden; Factor VIII; Venous thromboembolism; von Willebrand factor

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DNA; PROCOAGULANT; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM;

ADULT; FACTOR V; FACTOR VIII; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN C; RISK; RISK FACTORS; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0033405888     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. 1. Marlar RA, Kleiss AJ Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072.
2. 2. Walker FJ, Chavin S, Fay PJ. Inactivation of FVIII by activated protein C and protein S. Arch Biochem Biophys 1987; 252: 322-328.
3. 3. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1243.
4. 4. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738.
5. 5. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C / protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-4717
6. R506Q mutation. Thromb Haemost 1996; 76: 208-214.
7. 7. Broekmans AW, Veitkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344.
8. 8. Comp PC, Nixon RR, Cooper R, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
9. 9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant re-sponse to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
10. 10. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
11. 11. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg 506 Gln mutation in factor Va. Lancet 1994; 343: 1362-1363.
12. 12. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic thromboembolism with single point mutation at Arg 506 of factor V. Lancet 1994; 343: 1535-1536.
13. 13. Zöller B, Dahlbäck B, Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
14. 506Q is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-488.
15. 15. Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-482.
16. 16. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
17. 17. Trossaert M, Conard J, Horellon MH, Samama MM, Ireland H, Bayston TA, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
18. 18. Reitsma PH, van der Velden PH, Vogels E, van Strijp D, Tacker N, Adriaansen H, et al. Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a point mutation associated with APC-resistance. Blood Coagul Fibrinol 1996; 7: 659-663.
19. 19. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
20. 20. Koster K, Blann AD, Briet E, Vanderbrouke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
21. 21. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinol 1996; 7: 761-765.
22. 22. Tosetto A, Rodeghiero F, Martinelli I, De Stefano V, Missiaglia E, Chiusolo P, et al. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol 1998; 103: 871-876.
23. 23. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276
24. 24. Tosetto A, Missiaglia E, Gatto E, Rodeghiero F. The VITA Project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Thromb Haemost 1997; 78: 859-863.
25. 25. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323-327
26. 26. Mansvelt EPG, Laffan M, McVey JH, Tuddenham EGD. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost 1998; 80: 561-565.